Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1) - a randomized, placebo-controlled phase IIa dose escalation trial targeting disease tolerance to infection
Sebastian Weis, Luís Ferreira Moita, Daniel Thomas‐Rueddel, Peter Schlattmann et autres
de, pt, us, at (code pays fourni par la source)